Loading
companiesCompany
Luye Pharma Group
Luye Pharma is a Chinese pharmaceutical group, listed in Hong Kong, whose oncology business rests on paclitaxel liposome (Lipusu) and other reformulated cancer medicines.
Also called: Luye Pharma Group Ltd.Luye Pharma绿叶制药Shandong Boan Biotechnology Co., LtdBoan Biotech
Overview
Luye Pharma Group, based in Yantai in Shandong and listed on the Hong Kong stock exchange, develops and sells medicines in oncology, the central nervous system and cardiovascular disease, with a focus on new formulations and long-acting delivery. Its best-known cancer product is Lipusu, a liposomal formulation of paclitaxel widely used in China, and it runs phase 3 trials of reformulated chemotherapy and targeted agents. OnCo records it as a registry sponsor of phase 3 cancer trials.
Headquarters
Yantai, CN
Scorecard
All companies#129of 1244 companies, score 44
- approved products +6
- modalities +2
- regions +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 0 targets, 4,398 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.
Similar pages
- CompanyDaehwa Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Paclitaxel / nab-paclitaxel.
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyCyclacel Pharmaceuticals
fronts
drugs
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane
terms
trials
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaLPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS MutationLurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCStudy of LY01610 in Patients With Recurrent Small Cell Lung Cancer